ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

QLGN Qualigen Therapeutics Inc

0.284499
0.0011 (0.39%)
10 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Qualigen Therapeutics Inc QLGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0011 0.39% 0.284499 23:00:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.2778 0.264 0.2897 0.284499 0.2834
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202419:59EDGAR2Form S-1/A - General form for registration of securities..
16/4/202406:00GLOBEMarizyme Enters Into Co-Development Agreement With Qualigen..
10/4/202407:00GLOBEQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors..
09/4/202407:00GLOBEQualigen Therapeutics Announces Poster Featuring Positive..
27/2/202406:00EDGAR2Form 8-K - Current report
22/2/202415:10EDGAR2Form 8-K - Current report
07/12/202315:15EDGAR2Form 8-K - Current report
22/11/202315:30EDGAR2Form 8-K - Current report
14/11/202315:30GLOBEQualigen Therapeutics Provides Corporate Update for Third..
08/11/202313:16EDGAR2Form 8-K - Current report
07/11/202307:30GLOBEQualigen Therapeutics Announces First Patient Dosed in the..
23/10/202307:30GLOBEPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor..
17/10/202307:30EDGAR2Form 8-K - Current report
28/9/202315:15EDGAR2Form 8-K - Current report
27/9/202307:30GLOBEQualigen Therapeutics Presents Scientific Data on QN-302 at..
07/9/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
01/9/202315:15EDGAR2Form POS AM - Post-Effective amendments for registration..
17/8/202307:30GLOBEQualigen Therapeutics Partners with TD2 for Phase 1 Clinical..
15/8/202309:04EDGAR2Form 8-K - Current report
15/8/202307:30GLOBEQualigen Therapeutics, Inc. Reports Financial Results and..
14/8/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202315:30EDGAR2Form 8-K - Current report
01/8/202307:35EDGAR2Form 8-K - Current report
01/8/202307:30GLOBEQualigen Therapeutics Announces US FDA IND Clearance to..
26/7/202316:25EDGAR2Form 8-K - Current report
24/7/202307:15GLOBEQualigen Therapeutics Divests FastPack® Diagnostics Business
13/7/202316:29EDGAR2Form 8-K - Current report
07/7/202316:08EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
05/6/202307:15GLOBEPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor..
16/5/202307:00GLOBEQualigen Therapeutics, Inc. Reports Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock